Therapy of the Skeletal Disease of Type 2 Diabetes with Denosumab
Sponsor: |
Amgen Inc |
Enrolling: |
Female Patients Only |
Study Length: |
1 Years |
Clinic Visits: |
7 |
IRB Number: |
AAAR7827 |
U.S. Govt. ID: |
NCT03457818 |
Contact: |
Beatriz Omeragic: 212-304-5536 / bo2248@cumc.columbia.edu |
The purpose of this research study is to learn more about bone strength in women with type 2 diabetes, and to find out whether an experimental drug called Denosumab may help preserve bone strength. Type 2 Diabetes Mellitus (T2DM) has become one of the most important diseases of our time. Recent research shows that diabetes has negative effects on bones and that people with diabetes might be more likely to break a bone. We don't know the reasons for this, but we suspect that normal bone replacement is slowed down in diabetes and this could slow down the growth of new bone. This study will focus on attempting to lower the sugar-related components by treating a group of patients with type-2 diabetes with a medication Prolia or denosumab for one year. We will compare post-menopausal women both before and after denosumab use and study them in terms of different bone features based on blood tests, bone imaging, a bone indentation test and a measurement of sugar-related components in the skin. This study will help to clarify if using this medication helps improve bone strength in women with diabetes. Compensation: $225 dollars
This study is closed
Investigator
Mishaela Rubin, MD
Are you a postmenopausal woman with Diabetes? |
Yes |
No |
Are you interested in strengtening your bones? |
Yes |
No |